AU Patent

AU2022269659B2 — Erodible tablet

Assigned to Eli Lilly and Co · Expires 2025-04-10 · 1y expired

What this patent protects

The present invention relates to an erodible tablet comprising a therapeutic peptide which is suitable for oral administration and, in addition, to a non-granulation process for making the erodible tablet.

USPTO Abstract

The present invention relates to an erodible tablet comprising a therapeutic peptide which is suitable for oral administration and, in addition, to a non-granulation process for making the erodible tablet.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022269659B2
Jurisdiction
AU
Classification
—
Expires
2025-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.